Outcomes of Infant Medulloblastoma Treated With Standard‐Dose Chemotherapy—A Single‐Institution Experience From a Low‐Middle‐Income Country
- 22 September 2025
- journal article
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 72 (12) , e32056
Abstract
Background: Infant medulloblastoma (iMBL) is predominantly desmoplastic nodular (DN) or medulloblastoma with extensive nodularity (MBEN) histology, sonic hedgehog (SHH) driven. Intensified chemotherapy (intraventricular chemotherapy or high‐dose chemotherapy with autologous stem cell rescue) is recommended to compensate for the omission of radiation. This study aims to analyze the outcomes of iMBL treated without treatment intensification. Methods: This retrospective study was performed on 28 patients with iMBL (children with medulloblastoma n = 6, 21%). Half of the cohort had nonmetastatic disease. Sixteen patients had DN/MBEN histology. Only 68% ( n = 19) opted to continue postoperative treatment. Chemotherapy protocols used were baby SFOP, HIT SKK, and modified Packer. One fourth ( n = 7) received radiation (DN/MBEN = 3; other histology = 4) as a part of their initial treatment. There was no treatment‐related mortality. The 5‐year event‐free survival (EFS) of patients who received postoperative chemotherapy ± RT was 70% (those with DN/MBEN were 82.5% and non‐DN/MBEN were 35.7%). The 5‐year EFS of patients with DN/MBEN histology who received only chemotherapy ( n = 9) was 88.9%. Conclusions: Managing medulloblastoma in infants is challenging in LMIC, as a significant proportion of families opt against postoperative treatment. Although traditionally considered high risk, good survival can be achieved with non‐intensified therapy without an increase in treatment‐related mortality, especially in patients with DN/MBEN histology.Keywords
All Related Versions
This publication has 30 references indexed in Scilit:
- Efficacy of intrathecal methotrexate in children with high-risk medulloblastoma over three years: a retrospective study from a single centerJournal of Neuro-Oncology, 2023
- Review of the impact of molecular analysis on the therapy of medulloblastomaPediatric Hematology Oncology Journal, 2023
- The magnitude and predictors of therapy abandonment in pediatric central nervous system tumors in low‐ and middle‐income countries: Systematic review and meta‐analysisPediatric Blood & Cancer, 2019
- Intertumoral Heterogeneity within Medulloblastoma SubgroupsCancer Cell, 2017
- Pilot Study of Intensive Chemotherapy With Peripheral Hematopoietic Cell Support for Children Less Than 3 Years of Age With Malignant Brain Tumors, the CCG-99703 Phase I/II Study. A Report From the Children's Oncology GroupPediatric Neurology, 2015
- SIOP PODC adapted treatment recommendations for standard-risk medulloblastoma in low and middle income settingsPediatric Blood & Cancer, 2014
- Ommaya reservoir infection rate: a 6-year retrospective cohort study of Ommaya reservoir in pediatricsChild's Nervous System, 2014
- Molecular subgroups of medulloblastoma: the current consensusActa Neuropathologica, 2011
- Outcome of children less than three years old at diagnosis with non‐metastatic medulloblastoma treated with chemotherapy on the “Head Start” I and II protocolsPediatric Blood & Cancer, 2008
- Intrathecal chemotherapy for refractory disseminated medulloblastomaChild's Nervous System, 2007